

1 **Title Page**

2 **Title:** Gait biomechanics in Joint Hypermobility Syndrome: a spatiotemporal, kinematic and
3 kinetic analysis.

4 **Original Research.**

5 **Authors:** Najla Alsiri, PhD.^{a, b}, Mary Cramp, PhD ^a, Sue Barnett, PhD^a, and Shea Palmer
6 PhD^a.

7 ^aDepartment of Allied Health Professions, University of the West of England, Bristol, United
8 Kingdom

9 ^b Al-razi Orthopedic and Rehabilitation Hospital, Kuwait City, Kuwait.

10 **The research was conducted with the approval of the East Midlands, Leicester Research**
11 **Ethics Committee (14/EM/1008).**

12 **Corresponding author:** Dr. Najla Alsiri. Address: Al-razi Orthopedic and Rehabilitation
13 Hospital, Kuwait City, Kuwait. Email: dr.alsiri@outlook.com

14 Postal address: Sulibekhat – Jamal abdulnaser Str. P.O.Box: 5 – postal Code: 13001. Cable:
15 Health _ Kuwait.

16 **Acknowledgment:**

17 The study was funded by the Kuwait government as a part of PhD project and sponsored by
18 the University of the West of England, Bristol, United Kingdom. The authors acknowledge
19 Donna Wicks from the Hypermobility Syndrome Association, United Kingdom, Rachel Lewis
20 from North Bristol NHS Trust, United Kingdom, and Sin-ti Towlson from the Royal National
21 Hospital of Rheumatic Diseases, United Kingdom, for their support during patient recruitment.
22 The authors are grateful to the participants who took part in the research.

23 **Source of funding:** The study was funded as a PhD projects by the Kuwait Government.

24 **Conflict of interest statement:** The authors declare no conflict of interest.

25
26
27
28
29
30
31
32
33
34
35
36
37

38 Gait in Joint Hypermobility Syndrome

39 **Title:** Gait biomechanics in Joint Hypermobility Syndrome: a spatiotemporal, kinematic and
40 kinetic analysis.

41 **ABSTRACT**

42 **Background:** Joint Hypermobility Syndrome (JHS) symptoms of widespread joint
43 hypermobility and pain, muscle weakness and reduced muscle-tendon stiffness suggest that
44 there may be an impact on gait parameters. Identification of gait abnormalities may inform
45 assessment and management.

46 **Objective:** To explore the impact of JHS on gait parameters.

47 **Study design:** Cross-sectional design.

48 **Methods:** A JHS group of 29 participants (mean age 37.57 (S.D. 13.77) years) was compared
49 to a healthy control group of 30 participants (mean 39.27 (S.D. 12.59) years). Spatiotemporal
50 parameters, joint kinematics and joint kinetics were captured using the Qualisys motion capture
51 system synchronized with a Kistler force platform.

52 **Results:** Statistically significant reductions in walking speed, stride length and step length were
53 found in the JHS group, whilst stance and double support durations were significantly increased
54 ($p < 0.01$). During the swing phase, the JHS group showed significantly less knee flexion ($p <$
55 0.01). Reductions hip extensor moment, and knee power generation and absorption were
56 identified in the JHS group ($p < 0.01$). No other gait parameters were significantly altered.

57 **Conclusion:** The JHS group walked more slowly with a kinematic ‘stiffening’ pattern.
58 Hypermobility was not evident during gait. The observed stiffening pattern could be a strategy
59 to avoid pain and improve balance. Impairments in moment and power generation could be
60 related to several symptomatic and aetiological factors in JHS. Clinicians should carefully

61 consider gait in the assessment and management of people with JHS targeting the impairments
62 identified by the current study.

63 **Key words:** Joint Hypermobility Syndrome, kinematic, kinetic, gait, three-dimensional.

64 **Word count: 4548**

65

66

67

68

69

70

71

72

73

74

75

76

77

1. INTRODUCTION

79 Joint hypermobility syndrome (JHS) is an inherited connective tissue disorder in which
80 multiple synovial joints demonstrate symptomatic and excessive motion in the absence of
81 systemic inflammation (Hakim et al., 2004; Hakim and Grahame, 2003; Simmonds and Keer,
82 2007). JHS is multi-systemic, adversely affecting the musculoskeletal, cardiovascular,
83 digestive and autonomic nervous systems due to abnormalities in the connective tissues of these
84 systems, which changes their physiology (Hakim and Grahame, 2003). JHS is a severe and
85 disabling condition found in 30% of those referred to a musculoskeletal triage service in the
86 United Kingdom (Connelly et al., 2014). The hypermobility type of Ehlers-Danlos Syndrome
87 (EDS-HT) has been accepted as an identical condition to JHS, where the two are
88 indistinguishable (Ainsworth and Aulicino, 1993; Fatoye et al., 2012; Hakim et al., 2004;
89 Hakim and Grahame, 2003; Simmonds and Keer, 2007; Tinkle et al., 2009). Although both
90 JHS and EDS-HT were included in the present investigation, the term JHS will be used in most
91 instances to encompass both diagnostic terms. Although new diagnostic criteria were recently
92 introduced for hypermobility-related disorders (Castori et al., 2017; Malfait et al., 2017), the
93 current research was conducted before those criteria were available.

94 Gait is an important indicator of functional capacity and general health, and reflects the
95 integrity of visual, vestibular, proprioceptive, neuromusculoskeletal, cognitive and
96 psychological systems (Allum and Adkin, 2003; Buchner et al., 1996; Foroughi et al., 2008;
97 Lelas et al., 2003; Lemke et al., 2000; Patla, 1998; Rigoldi et al., 2012; Riskowski et al., 2005).
98 Gait analysis can identify the functional impact of health conditions (Lelas et al., 2003;
99 Flansbjer et al., 2006). The gait of people with JHS could theoretically be altered due to laxity
100 in the connective tissues of their joints' supportive structures (Hakim and Grahame, 2003;
101 Simmonds and Keer, 2007). Laxity is caused by mutation in the genes encoding collagen and
102 abnormalities in the enzymes responsible for collagen modification essential for maintaining

103 the mechanical rigidity and stability of joints (Grahame, 2009; Malfait et al., 2006). JHS may
104 also be associated with mutation in tenascin-X, which is prevalent in musculoskeletal tissues
105 and bridges between collagen fibers (Malfait et al., 2006). Tenascin-X is essential for collagen
106 formation and regulation (Malfait et al., 2006). It is therefore hypothesized that collagen
107 deficiency in ligamentous and musculotendinous tissues is responsible for joint hypermobility
108 and instability in JHS and will impact on lower limb joint biomechanics and spatiotemporal
109 parameters during walking.

110 Symptoms such as joint pain and instability, fatigue, muscle weakness, proprioceptive
111 deficits, and physical and psychological decline (such as depression and anxiety) might also
112 have an impact on the gait of people with JHS (Fatoye et al., 2012; Hakim and Grahame, 2003;
113 Rombaut et al., 2010; Toker et al., 2010). For example, chronic widespread pain in JHS could
114 inhibit the motor system and cause muscular weakness (Le Pera et al., 2001). Knowledge of
115 the relationship between joint pain, instability and gait parameters has previously helped to
116 inform the management of patients with Anterior Cruciate Ligament (ACL) injuries and knee
117 osteoarthritis. For example, people with ACL injuries were found to avoid quadriceps
118 contraction to control tibial forward translation (Berchuck et al., 1990; Hart et al., 2009; Jensen
119 et al., 2013) and people with osteoarthritis reduced their joint moment as a strategy to cope
120 with pain (Hurwitz et al., 1997). Such symptoms of joint instability and pain are also features
121 of JHS and could alter gait in people with the condition. Investigating gait parameters could
122 therefore provide greater understanding of functional deficits in JHS and help to direct
123 rehabilitation interventions toward specific gait impairments that might be identified.

124 Few studies have previously explored gait in adults with JHS/EDS-HT (Celletti et al.,
125 2012; Galli et al., 2011; Rigoldi et al., 2012). All previous studies used three-dimensional
126 motion analysis, which is the gold standard for assessment of movement with excellent
127 clinimetric properties through standardized, well described and evidence-based methods

128 (Celletti et al., 2012; Connell, et al., 2004; Ingemarsoon et al., 2003; Jensen et al., 2013).
129 Previous studies explored specific gait components (Celletti et al., 2012; Galli et al., 2011;
130 Rigoldi et al., 2012). Galli et al., (2011) examined 12 men and women with JHS/EDS-HT and
131 found significant reductions in step length and ankle dorsiflexion in the JHS/EDS-HT group
132 when compared to the control group. Rigoldi et al., (2012) compared 12 patients with EDS-HT
133 with 20 healthy controls and demonstrated significant reductions in step length, ankle
134 plantarflexion and hip power. Celletti et al., (2012) examined 21 women with JHS/EDS-HT
135 and used the Gait Profile Score to represent gait kinematic differences, identifying lower
136 physiological gait for the hip, knee and ankle overall kinematics in the JHS group.

137 The current study advances these reports; it provides a comprehensive three-
138 dimensional gait analysis, including spatiotemporal, kinematic and kinetic parameters of the
139 lower limb joints, uses clinically confirmed diagnostic criteria and has a justified sample size.
140 Such comprehensive analysis of the entire lower limb joints is important because JHS affects
141 the entire musculoskeletal system, rather than isolated individual joints. The findings of the
142 current study could identify specific gait impairments in JHS to direct the rehabilitation
143 programs, therefore optimizing the provided management and improving patient activity level.
144 Consequently, the primary objective of the current study was therefore to explore the impact
145 of JHS on spatiotemporal parameters and lower limb joint biomechanics (kinematics and
146 kinetics) in adults, through a comparison with a control group. A secondary objective was to
147 investigate the correlation between joint pain, as the predominant impairment in JHS, and
148 spatiotemporal and biomechanical parameters.

149 **2. METHODS**

150 **2.1 Participants**

151 The research was approved by the East Midlands, Leicester Research Ethics Committee
152 (14/EM/1008) in accordance with The Code of Ethics of the World Medical Association
153 (Declaration of Helsinki). Informed written consent was obtained from participants and their
154 privacy rights was observed. Ambulatory men and women aged ≥ 18 years were included. The
155 exclusion criteria were: lower back or lower limb injuries during the last three months as so to
156 not interrupt the healing process (Connell et al., 2004), fracture in the lower limbs during the
157 last 12 months as this could affect walking speed and balance (Ingemarsson et al., 2003);
158 pregnancy; and giving birth during the last year due to postpartum ligament laxity (Romabut et
159 al., 2011). Participants were excluded from the control group if they had generalized joint laxity
160 ($\geq 4/9$ in the Beighton score); pain (within the last three months) in the lower back or lower
161 limb joints (Connelly et al., 2014); or had a connective tissue disorder or other conditions which
162 cause weakness in the lower limbs.

163 People with JHS were recruited from the Hypermobility Syndromes Association
164 (HMSA) (a UK patient organization), and two secondary care hospitals in South West England,
165 UK. Participants in the control group were recruited via an email advert to staff and students
166 of the University of the West of England, Bristol, UK (UWE), and their relatives and friends.
167 Recruitment packs were sent to potential participants, and those who were willing to take part
168 in the study returned a reply slip to the research team. The diagnosis of JHS was initially self-
169 declared by patients then confirmed clinically by the chief investigator (NA) using the Brighton
170 criteria for JHS and the Revised Nosology of Villefranche for EDS-HT (Brighton et al., 1998;
171 Hakim et al., 2004; Hakim and Grahame, 2003; Simmonds and Keer, 2007). A matching pair
172 design for control participants with a frequency distribution control method was followed to
173 ensure between-group homogeneity in terms of age and sex.

174 Prospective sample size calculations were informed by available published data, from
175 which representative effect sizes could be calculated to investigate the study hypothesis of an

176 impact of JHS on gait spatiotemporal parameters and biomechanics when compared to a control
177 group. For spatiotemporal parameters, Galli et al. (2011) found a significant reduction in step
178 length in JHS, with an observed effect size of 0.84. For kinematic parameters, Rigoldi et al.,
179 (2012) reported a significant difference for ankle dorsiflexion, with an effect size of 0.74.
180 Finally, for kinetic parameters, Galli et al. (2011) found a reduction in plantar flexor moment
181 during the terminal stance phase, with an effect size of 0.70. The smallest effect size of 0.70
182 was thus used as a realistic basis for the sample size calculation (corresponding to a moderate
183 to large SMD). Sample size was estimated to be a minimum of 26 participants per group at α
184 = 0.05 and 80% power. A target sample of 30 per group was set to allow for up to 20% attrition.

185 **2.2 Instrumentation**

186 A Qualisys™ motion capture system (Qualisys, Gothenburg, Sweden) was used to
187 capture movement kinematics through ten infrared cameras (Oqus 3+) and Qualisys Track
188 Manager software (QTM). Instrument settings were checked and calibration was performed
189 before each session according to the manufacturer guidelines. A Kistler force platform
190 (Multicomponent force plate type 9281E, Kistler Group, Eulachstrasse, Swizerland) was
191 synchronised with the Qualisys system to identify gait events and kinetics along with the
192 trajectory analysis. The Qualisys™ system captures data with high validity, reliability, and
193 precision (Everaert et al., 1999; Yavuzer et al., 2008; Kejonen and Kauranen, 2002; Sinclair et
194 al., 2012). Good to excellent intra-rater reliability (ICC ranged from 0.625-0.996) of the
195 kinematics of lower limb joints was demonstrated in the current study for repeated marker
196 placement and repeating the walk test in ten participants from the control group (Alsiri, 2017).
197 Average pain intensity experienced over the last week was assessed using Visual Analogue
198 Scales (VAS) for the hip, knee and ankle joints. VAS is a simple tool with high validity and
199 reliability (Lara-Munoz et al., 2004; Williamson and Hoggard, 2005).

200 **2.3 Data collection and analysis**

201 Data collection was conducted at the Human Analysis Laboratory, University of the
202 West of England (UWE), Bristol. The same researcher (NA) conducted the examination to
203 eliminate inter-rater variability. Infrared retro-reflective markers, and four marker clusters were
204 attached to the lower limb joints to define their segmental coordinate systems and track
205 segmental motion following the Calibrated Anatomical System Technique (CAST) (Cappozzo
206 et al., 1995). Joint angles were determined using the joint co-ordinate system. A static trial was
207 recorded, prior to the collection of dynamic trials for calculation of relevant segmental co-
208 ordinate systems. Each participant was then asked to walk along a 10 m walkway at self-
209 selected walking speed starting with three trials for familiarization. Self-selected walking speed
210 was examined to allow the observation of natural walking patterns of people with JHS. Five
211 trials of each limb were recorded with clear contacts with the force plate, which is sufficient to
212 obtain good reliability; ICC > 0.7 (Laroche et al., 2011). Twenty seconds rest was provided
213 between trials to minimise fatigue (Orendurff et al., 2008).

214 Data were processed using the QTM software to display and identify the markers'
215 trajectories and their six degrees of freedom using the Automatic Identification Model. Each
216 gait event was labelled, and foot contact and foot off gait events were labelled to identify
217 stance and swing phases. A low-pass filter was used to remove the noise without affecting the
218 true signals. The output was transmitted to a computer through analogue-digital converter,
219 then to QTM and sampled at a frequency of 100 Hz. After events processing the data were
220 converted to C3D files and transferred and processed in Visual 3D software to produce
221 kinematic and kinetic curve graphs. Data normalized to gait cycle within Visual 3D, were
222 exported in ASCii format to Microsoft Excel.

223 Statistical Package for the Social Science (SPSS version 22, IBM corp.) was used for
224 statistical analysis. Histograms and Shapiro-Wilk tests were used to assess data normal

225 distribution (Field, 2009). Independent t-tests were used for the normally distributed data to
226 analyse differences between groups, and Mann-Whitney U tests were used for non-normally
227 distributed data (Field, 2009). Inferential statistics were used to compare the JHS group against
228 the control group in terms of gait spatiotemporal parameters including walking speed, stride
229 and step length, stance time duration, double support time, initial double support time, and
230 terminal double support time. The two groups were compared in terms of gait kinematics of
231 the pelvic, hip, knee and ankle joints in the frontal, sagittal and transverse planes. Gait kinetics,
232 namely moments and powers, were also compared at the hip, knee and ankle joints in the three
233 planes of movement. To reduce the risk of type I error due to multiple comparisons, the alpha
234 was reduced to 0.01 (Pallant, 2010). Therefore, statistically significant differences were
235 identified when $p \leq 0.01$.

236 Standardised mean differences (SMDs) was reported with 95% confidence interval (CI)
237 to quantify the size of the differences (Cohen, 1988; Samsa et al., 1999; Walker, 2007). A SMD
238 of 0.2 suggests a small difference, 0.5 suggests a moderate difference, and 0.8 suggests a large
239 difference (Cohen, 1988). SMDs of 0.5 and higher are highlighted in bold in the tables (tables
240 2-5). To make the data more accessible, only analyses for the right leg are presented in this
241 manuscript, as there were no statistically significant differences between right and left limbs.
242 Pearson Product Correlation Coefficients were used to correlate joint pain with gait
243 parameters. A confounded analysis was performed with multiple regressions to examine the
244 potential influence of age, body weight, and joint pain (back, hip, knee and ankle pain), with
245 gait parameters found to be significantly different in the JHS group.

246 **3. RESULTS**

247 **3.1 Demographic and pain data**

248 Participant demographic characteristics, reported in table 1, indicate that the groups
249 were largely similar. Significant differences were found between the two groups in the
250 Beighton score, as would be expected. The JHS group showed statistically significant increase
251 in the pain intensity experienced at the hip, knee and ankle joints during both rest and
252 movement when compared to the control group; $p = 0.001$ (Table 1).

253 Table one will be inserted here -----

254 3.2 Spatiotemporal parameters

255 Statistically significant differences were found for the JHS group in walking speed,
256 initial double support duration and terminal double support duration (table 2). The SMDs were
257 moderate to large for the majority of those differences (table 2).

258 Table two will be inserted here -----

259 3.3 Kinematic gait analysis

260 No statistically significant differences were identified between the two groups for
261 pelvic and hip kinematics (table 3). The SMDs suggested a moderate reduction in pelvis
262 upward obliquity and hip abduction in the JHS group during the swing phase (table 3). A
263 statistically significant reduction was found in knee flexion during the swing phase in the JHS
264 group and the SMD suggested a moderate difference (table 4), this change was illustrated
265 graphically (figure 1). No graphical observations nor statistical differences were highlighted
266 for ankle kinematics (table 4).

267 Table three will be inserted here -----

268 Table four will be inserted here -----

269 Figure 1 will be inserted here -----

270 **3.4 Kinetic gait analysis**

271 The statistical analysis identified significant reductions in the JHS group when
272 compared to the control group in hip extensor moment, knee power generation in the sagittal
273 plane, and knee power absorption in the transverse plane (table 5). These changes are illustrated
274 graphically in figure 2. The SMDs suggested moderate differences between the two groups in
275 hip extensor and internal rotator moments (table 5). Moderate to large differences were
276 identified between the groups as suggested by the SMDs in knee extensor, internal rotator, and
277 external rotator moments, and knee power generation in the sagittal plane and knee power
278 absorption in the transverse plane (table 5).

279 Table 5 will be inserted here -----

280 Figure 2 will be inserted here -----

281 **3.5 Joint pain**

282 The most common painful joint in the JHS group was the knee joint (90.32% of
283 participants), followed by the hip joint (83.87%) and the ankle joint (77.41%). Relationships
284 proved to be statistically significant were only reported, where joint pain was significantly
285 correlated ($p < 0.05$) to walking speed, stride length and stance duration percentage. Moderate
286 correlations were found between stance duration percentage and hip and ankle joint pain ($r =$
287 0.436 and 0.446 respectively). Very weak to weak correlations were found between joint pain
288 and gait kinematics (r -values ranged 0.005 to 0.281).

289 **3.6 Confounded analysis:**

290 The results of multiple regression (Table 6) showed that the established model of the
291 influence of age, body weight and joint pain explains 16.2% of the variance in gait speed,

292 13.6% of the variance in maximum knee flexion during the swing phase, 12.3% of the variance
293 in hip maximum moment at the sagittal plane, 16.8% of the variance in knee maximum power
294 generation in the sagittal plane, and 30.4% of the variance in knee minimum power absorption
295 in the transverse plane (Table 6). However, none of the models reached statistical significance
296 except for the knee power absorption model ($p = 0.003$). Beta Standardized Coefficients were
297 the highest for joint pain but only knee pain in knee minimum power absorption model reached
298 statistical significance ($p = 0.007$).

299 Table 6 will be inserted here -----

300 4. DISCUSSION

301 A range of spatiotemporal parameters were significantly different with large effect
302 sizes in the JHS group compared to the control group, including walking speed, stride length,
303 step length, initial double support time and terminal double support time. A statistically
304 significant reduction with medium effect size was identified in the JHS group's kinematics in
305 knee flexion during the swing phase. Simultaneously, statistically significant reductions with
306 medium to large effect sizes were shown in the JHS group in hip extensor moment, knee
307 power generation in the sagittal plane, and knee power absorption in the transverse plane.
308 Multiple regression analyses of the current study indicated that joint pain could be the main
309 influence on joint biomechanics.

310 Spatiotemporal parameters for adults with JHS were explored in one previous study.
311 Galli et al., (2011) reported a significant reduction in the EDS-HT group's step length with
312 no significant difference in stance phase duration and velocity. The current investigation
313 contradicts Galli et al., (2011), as a significant reduction in walking speed, and a significant
314 increase in double support time and terminal double support time were identified. Galli et al.,
315 (2011) used a small sample size of 12 participants with EDS-HT versus 20 controls exposing

316 their results to possible type II error. Galli et al., (2011) also did not clarify their patient
317 diagnostic criteria which may have created differences in sample characteristics between the
318 two studies.

319 The significant changes in the JHS group's spatiotemporal parameters could be
320 explained by joint pain and reduced power as these factors have previously been identified as
321 being significantly correlated with walking speed (Chen et al., 1997; Lusa, et al., 2015; Purser
322 et al., 2012). Adopting a pattern of increasing the double support duration in JHS could be a
323 strategy to avoid joint pain, stress and load (Debi et al., 2009), where correlations were found
324 in the current study between stance duration percentage and hip and ankle joint pain.
325 Significant reductions in hip moments and knee power generation and absorption, identified in
326 the current study, could explain the alterations in spatiotemporal parameters. We have
327 previously reported (Alsiri, 2017) the predicted effect of differences in walking speed on
328 kinetic parameters using the regression equations of Lelas et al., (2003). All predicted
329 differences were less than the actual observed differences. Therefore, although speed may have
330 been a factor, it is insufficient to explain the differences between groups. It should be noted,
331 however, that regression equations were not available for all kinetic parameters investigated in
332 our study.

333 A 'stiffening' pattern was evident in people with JHS, identified as the stiffening of
334 hypermobile joints to act as normally mobile joints during the stance phase of walking. Most
335 of the descriptive statistics, graphical observations, and the SMDs suggested that the JHS
336 group's kinematics were either comparable or reduced when compared with the control group
337 and provides some support for this pattern. Stiffening was also evident as a reduction in gait
338 kinematics during the swing phase. There was a statistically significant reduction in knee
339 flexion, and the SMDs suggested moderate reductions in pelvic upward obliquity and hip

340 abduction. The similarities found in the graphs between the control group and the JHS group
341 (despite joint hypermobility) further support this stiffening pattern.

342 The concurrent statistical reductions in joint moments and powers, along with
343 kinematic stiffening, could suggest a relationship between the kinematic and kinetic
344 observations in JHS. Kinetic reductions in the JHS group could be related to collagen and
345 protein genetic abnormalities, muscle weakness, reduction in musculoskeletal stiffness and/or
346 pain-motor inhibition (Hakim and Grahame, 2003; O’Connell et al., 2010; Rombaut et al.,
347 2012; Sahin et al., 2008; Scheper et al., 2013; Syx et al., 2015; Voermans et al., 2009; Alsiri et
348 al., 2019). The kinetic reductions identified in the JHS group could be an avoiding behavior
349 employed intentionally to avoid joint hypermobility and pain, which might also explain the
350 stiffening observed in the kinematic analysis. The avoiding behavior theory was first described
351 by Berchuck et al., (1990) as “quadriceps avoidance” theory and was further supported by a
352 study in people with ACL injuries (Berchuck et al., 1990; Hart et al., 2009; Jensen et al., 2013).
353 This pattern is adopted by people with ACL injury by reducing the contraction of the
354 quadriceps to control tibial forward translation (Hart et al., 2009). Such a theory could be
355 applied to people with JHS as they may share some instability features with the ACL
356 population. Such behavior is also noticed in people with osteoarthritis, where moments are
357 reduced during walking and this has been referred to as a pain coping strategy (Hurwitz et al.,
358 1997). The stiffening pattern we have observed could be further explored through
359 electromyographic studies to understand the contribution of the lower limb musculature.

360 The current study analysed the gait kinematics of people with JHS in three planes of
361 movement. Therefore, there are several parameters that could not be compared with the existing
362 literature. Gait kinematics in adults with JHS were explored in two studies previously, where
363 mostly sagittal plane kinematics were reported. The results of the first study of Galli et al (2011)
364 support the stiffening pattern we observed, as functional joint hypermobility was not

365 demonstrated in the EDS-HT group. Specifically, no significant differences between EDS-HT
366 and the control group were found for the pelvis, hip and knee kinematics during the stance
367 phase, except for ankle dorsiflexion which was significantly reduced. The second available
368 study of Celletti et (2012) further supports the stiffening pattern, as the kinematic parameters
369 were physiologically reduced when compared to the control group. However, comparing the
370 current results with those of Celletti et al (2012) might be inappropriate due to differences in
371 data reporting; they used the Gait Profile Score, a single index for gait alterations.

372 There has been no previous report exploring hip and knee moments and powers during
373 the gait cycle in people with JHS. Galli et al., (2011) reported significant reductions in the ankle
374 plantar flexors' moment and power generation in the EDS-HT group. The reductions observed
375 in the current study failed to reach statistical significance. The contrast in findings might be
376 related to the heterogeneous age of the groups investigated by Galli *et al.* (2011) (mean \pm SD
377 age of the EDS-HT group was 43.08 ± 6.78 and in the control group was 37.23 ± 8.91 years)
378 (Galli et al., 2011), with the reduced moment and power generation in the JHS group being
379 related to their older age. However, our study also observed reduced ankle plantar flexors
380 moment and ankle power generation in the JHS group that did not reach statistical significance.
381 The associated SMDs suggested small to medium differences which may indicate type II error
382 in our results.

383 Previous biomechanical explorations in JHS were limited, therefore, the findings of
384 reduced kinetic values have been compared against other musculoskeletal conditions. Analysis
385 has previously revealed moment reductions in people with osteoarthritis, with the exception of
386 a significant increase in knee adductor moment, and ACL injuries like JHS (Hurwitz et al.,
387 1997; Hart et al., 2009; Toker et al., 2010). ACL injuries may be more comparable with JHS
388 due to sharing the instability feature. People with JHS might adopt stiffening as a pain-avoiding
389 behavior to avoid over-stressing the joints and inducing pain. Joint laxity and hypermobility

390 are major contributors to the pathogenesis of pain (Acasuso-Diaz and Collantes-Esteez, 1998).
391 Overstretching the joint structures could induce micro-trauma, inflammation and pain, which
392 can be complicated with repetitive over-stretching causing overuse injuries and a vicious cycle
393 of pain (McMaster, 1996; Smith, 2005). Stiffening could be adopted to control the
394 hypermobility-pain cycle. People with JHS might adopt stiffening during walking due to their
395 fear of falling, as controlling their walking kinematics could improve their balance, where 95%
396 of the participants in the EDS-HT group in Rombaut et al.'s (2011) study had fallen during the
397 previous year. Kinematic reduction in the swing limb could be adopted as a load reduction
398 strategy employed to reduce joint stress and pain and improve equilibrium (Mundermann et
399 al., 2005; Simic et al., 2011). Balance is a critical problem in people with JHS, and it is
400 associated with increased falling frequency (Rombaut et al., 2011). Such a strategy of reducing
401 the leg opening by reducing pelvic upward obliquity and hip abduction maintains the center of
402 mass within the base of support, could maintain equilibrium (Cappozzo et al., 1995; Lee and
403 Farley, 1998). Moreover, medio-lateral trajectory of the center of mass is influenced by hip
404 abduction/adduction to control medio-lateral equilibrium (Winter, 1995).

405 The current study has comprehensively explored gait parameters in people with JHS,
406 including spatiotemporal, kinematic and kinetic parameters for the entire lower limbs. The
407 study used a gold standard three-dimensional motion analysis, valid diagnostic criteria and a
408 standardized protocol. In addition, a conservative alpha level of 0.01 was employed for
409 statistical significance to reduce the risk of type I error due to multiple comparisons. However,
410 the study is limited by several factors. The cross-sectional design employed in the current study
411 can be used to examine relationships and associations, however, this design is unable to
412 determine cause and effect relationships (Hennekens and Buring, 1987). It was not practical to
413 blind the lead researcher, which might risk exposing the results to expectation bias (Bailey,
414 1997; Bowling, 2009), and gait kinematics were not normalised to speed (Lelas et al., 2003;

415 Kwon et al., 2015). The sample was based on a priori sample size calculations, however the
416 medium to large effect size of 0.70 used in the calculation, in conjunction with the use of a
417 conservative alpha level, may have exposed the study to type II errors. A study with a larger
418 sample size would be needed to explore any observations that failed to reach statistical
419 significance. The reduced kinetics observed in the JHS group might be related to the fact that
420 the JHS group walked more slowly than the control group (Ardestani et al., 2016). This factor
421 has not been corrected for and this should be considered when interpreting the kinetics findings.

422 Clinicians should carefully consider gait in the assessment and management of people
423 with JHS, particularly understanding and improving the relationships between joint pain and
424 the stiffening gait pattern. Rehabilitation programs could be directed towards improving joint
425 control through specific and functional strength training for dynamic stabilizer muscles and
426 gradually increasing walking speed. The success of gait training should be assessed via effects
427 on pain and reducing the dependency on the stiffening pattern. Future studies are needed to
428 understand the long-term effects of the stiffening pattern on potential muscle weakness,
429 instability and pain and to evaluate the effectiveness of gait training.

430 5. CONCLUSION

431 Multiple gait impairments were revealed in people with JHS, including reduced
432 walking speed, altered spatiotemporal parameters, stiffened kinematics and reduced moments
433 and powers. Future research is needed to determine the effects of the observed stiffening pattern
434 on the long-term symptoms and progression of the condition. The identified impairments could
435 be targeted during gait rehabilitation to improve activity and participation.

436

437

438

6. CONFLICT OF INTEREST

439 The authors declare no conflict of interest.

440

441

7. REFERENCES

- 442 1. Acasuso-Diaz M, Collantes-Esteez E. Joint hypermobility in patients with fibromyalgia
443 syndrome. *Arthritis Care Res.* 1998;11(1):39-42 .
- 444 2. Ainsworth S, Aulicino, P. A survey of patients with Ehlers-Danlos syndrome. *Clin*
445 *Orthop Relat Res.* 1993;286:250-256 .
- 446 3. Allum J, Adkin A. Improvements in trunk sway observed for stance and gait tasks during
447 recovery from an acute unilateral peripheral vestibular deficit. *Audiol Neurotol.*
448 2003;8(5):286-302 .
- 449 4. Alsiri N. The impact of joint hypermobility syndrome in adults: a quantitative
450 exploration of neuromuscular impairments, activity limitations and participation
451 restrictions. 2017. University of the West of England, Bristol.
452 http://eprints.uwe.ac.uk/30112/18/Thesis_Najla_4RegistryV2.pdf
- 453 5. Alsiri N, Al-Obaidi S, Asbeutah A, Almandeel M, Palmer S. The impact of
454 hypermobility spectrum disorders on musculoskeletal tissue stiffness: an exploration
455 using strain elastography. *Clin Rheumatol.* 2019;38(1):85-95.
- 456 6. Ardestani M, Ferrigno C, Moazen M, Wimmer M. From normal to fast walking: impact
457 of cadence and stride length on lower extremity joint moments. *Gait and Posture.*
458 2016;46:118-125.
- 459 7. Bailey D. 1997. *Research for health professional: a practical guide.* 2nd ed. Philadelphia:
460 F.A. Davis Company .
- 461 8. Berchuck M, Andriacchi T, Bach B, Reider B. Gait adaptation by patients who have a
462 deficient anterior cruciate ligament. *Journal of Bone and Joint Surgery.* 1990;72(6):871-
463 877.
- 464 9. Bowling A. 2009. *Research methods in health: investigating health and health services.*
465 3rd ed. England: The McGraw-Hill Companies .
- 466 10. Brighton P, Paepe A, Steinmann B, Tsipouras P, Wenstrup R. Ehlers-Danlos syndrome:
467 Revised Nosology, Villefranche, 1997. *Am J Med Genet.* 1998;77:31-37 .
- 468 11. Buchner D, Larson E, Wagner E, Koepsell T, Lateur B. Evidence for a non-linear
469 relationship between leg strength and gait speed. *Age Aging.* 1996;25(5):386-391.
- 470 12. Cappozzo A, Catani F, Croce U, Leardini A. Position and orientation in space of bones
471 during movement: anatomical frame definition and determination. *Clin Biomech.*
472 1995;10(4):171-178 .
- 473 13. Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A. A framework for the
474 classification of joint hypermobility and related conditions. *Am J Med Genet C Semin*
475 *Med Genet.* 2017;175(1):148-157.
- 476 14. Celletti C, Galli M, Cimolin V, Castori M, Albertini G, Camerota F. Relationship
477 between fatigue and gait abnormality in joint hypermobility syndrome/Ehlers-Danlos
478 syndrome hypermobility type. *Res Dev Disabil.* 2012;33(6):1914-1918.
- 479 15. Chen I, Kuo K, Andriacchi T. The influence of walking speed on mechanical joint
480 power during gait. *Gait Posture.* 1997;6:171-176.
- 481 16. Cohen J. 1988. *Statistical power analysis for behavioural sciences.* 2nd edition. USA:
482 Lawrence Erlbaum Associates.

- 483 17. Connell D, Schneider-Kolsky M, Hoving J, Malara F, Buchbinder R, Koulouris G,
484 Burke F, Bass C. Longitudinal study comparing sonographic and MRI assessments of
485 acute and healing hamstring injuries. *AJR Am J Roentgenol*. 2004;183(4):975-984.
- 486 18. Connelly E, Hakim E, Davenport S, Simmonds J. A study exploring the prevalence of
487 Joint Hypermobility Syndrome in patients attending a Musculoskeletal Triage Clinic.
488 *Physiotherapy Practice and Research*. 2014;36(1):43-53.
- 489 19. Debi R, Mor A, Segal O, Segal G, Debbi E, Agar G, Halperin N, Haim A, Elbaz, A.
490 Differences in gait pattern, pain, function and quality of life between males and females
491 with knee osteoarthritis: a clinical trial. *Musculoskeletal Disorders*. 2009;10(127).
- 492 20. Everaert D, Spaepen A, Wouters M, Stappaerts K, Oostendrop R. Measuring small
493 linear displacements with a three-dimensional video motion analysis system:
494 determining its accuracy and precision. *Arch Phys Med Rehabil*. 1999;80(9):1082-
495 1089 .
- 496 21. Fatoye F, Palmer S, Macmillan F, Rowe P, Van der Linsen M. Pain intensity and quality
497 of life perception in children with hypermobility syndrome. *Rheumatol Int*.
498 2012;32:1277-1284 .
- 499 22. Ferrell W, Tennant N, Sturrock R, Ashton L, Greed G, Brydson G, Rafferty D.
500 Amelioration of symptoms by enhancement of proprioception in patients with joint
501 hypermobility syndrome. *Arthritis Rheum*. 2004;50(10):3323-3328 .
- 502 23. Field A. 2009. *Discovering statistics using SPSS*. 3rd ed. London: SAGE publication.
- 503 24. Flansbjer U, Downham D, Lexell J. Knee muscle strength, gait performance, and
504 perceived participation after stroke. *Physical Medicine and Rehabilitation*.
505 2006;87(7):974-980 .
- 506 25. Foroughi N, Smith R, Vanwanseele B. The association of external knee adduction
507 moment with biomechanical variables in osteoarthritis: A systematic review. *The Knee*.
508 2008;16(5):303-309.
- 509 26. Fritz S, Lusardi M. White paper: “walking speed: the sixth vital sign”. *J Geriatr Phys*
510 *Ther*. 2009;32(2):2-5 .
- 511 27. Galli M, Cimolin V, Rigoldi C, Castori M, Celletti C, Albertini G, Camerota F. Gait
512 strategy in patients with Ehlers-Danlos syndrome hypermobility type: a kinematic and
513 kinetic evaluation using 3D gait analysis. *Res Dev Disabil*. 2011;32:1663-1668.
- 514 28. Grahame R. Joint hypermobility syndrome pain. *Current Pain and Headache Reports*.
515 2009;13:427-433.
- 516 29. Hakim A, Cherkas L, Grahame R, Spector T, MacGregor A. The genetic epidemiology
517 of joint hypermobility: a population study of females twins. *Arthritis & Rheum*.
518 2004;50 (8):2640-2644 .
- 519 30. Hakim A, Grahame R. 2003. Joint hypermobility. *Best Pract Res Clin Rheumatol*.
520 2003;17(6):989-1004.
- 521 31. Hall, S. (1999) *Basic biomechanics*. 3rd ed. United States: McGraw Hill.
- 522 32. Hart J, Ko J, Konold T, Pietrosimione B. Sagittal plane knee joint moments following
523 anterior cruciate ligament injury and reconstruction: A systematic review. *Clinical*
524 *Biomechanics*. 2009;25:277-283.
- 525 33. Hennekens CH, Buring JE. *Epidemiology in Medicine*, Lippincott Williams & Wilkins,
526 1987.
- 527 34. Hurwitz D, Hulet C, Andriacchi T, Rosenberg A, Galante J. Gait compensations in
528 patients with osteoarthritis of the hip and their relationship to pain and passive hip
529 motion. *Journal of Orthopaedic Research*. 1997;15:629-635 .
- 530 35. Ingemarsson A, Frandin K, Mellstrom D, Moller M. Walking ability and activity level
531 after hip fracture in elderly- a follow-up. *J Rehabil Med*. 2003;35 (2):76-83.

- 532 36. Jensen B, Olesen A, Pedersen M, Kristensen J, Remvig L, Simonsen E, Juul-Kristensen
533 B. Effect of generalised joint hypermobility on knee function and muscle activation in
534 children and adults. *Muscle Nerve*. 2013;48(5):762-769 .
- 535 37. Judge J, Ounpuu S, Davis R. Effects of age on the biomechanics and physiology of gait.
536 *Clinics in Geriatrics Medicine*. 1996;12(4):659-678 .
- 537 38. Kejonen P, Kauranen K. Reliability and validity of standing balance measurements with
538 a motion analysis system. *Physiotherapy*. 2002;88(1):25-32.
- 539 39. Kwon J, Son S, Lee N. Changes of kinematic parameters of lower extremities with gait
540 speed: a 3D motion analysis study. *J Phys Ther Sci*. 2015;27(2):477-479.
- 541 40. Lara-Munoz, C., Leon, S., Feinstein, A., Puente, A. and Wells, C. (2004) Comparison
542 of three rating scales for measuring subjective phenomena in clinical research. *Archives*
543 *of Medical Research*. 35 (1), pp. 43-48.
- 544 41. Laroche D, Duval A, Morisset C, Beis J, d'Athis P, Maillefert J, Ornetti P. Test-retest
545 reliability of 3D kinematic gait variables in hip osteoarthritis patients. *Osteoarthritis*
546 *Cartilage*. 2011;19:194-199.
- 547 42. Le Pera, D., Graven-Nielsen, T., Valeriani, M., Oliviero, A., Lazzaro, V., Tonali, P. and
548 Arendt-Nielsen, L. (2001) Inhibition of motor system excitability at the cortical and
549 spinal level by tonic muscle pain. *Clinical Neurophysiology*. 112 (9), pp. 1633-1641.
- 550 43. Lee, C. R., Farley, C. T., 1998. Determinants of the center of mass trajectory in human
551 walking and running. *J Exp Biol*. 201, pp. 2935-2944.
- 552 44. Lelas J, Merriman G, Riley P, Kerrigan D. Predicting peak kinematic and kinetic
553 parameters from gait speed. *Gait Posture*. 2003;17(2):106-112.
- 554 45. Lemke M, Wendorff T, Mieth B, Buhl K, Linnemann M. Spatiotemporal gait pattern
555 during over ground locomotion in major depression compared with healthy control.
556 *Journal of Psychiatric Research*. 2000;34(4-5):277-283.
- 557 46. Lusa A, Amigues I, Kramer H, Dam T, Giles J. Indicators of walking speed in
558 rheumatoid arthritis: relative influence of articular, psychological, and body
559 composition characteristics. *Arthritis Care Res (Hoboken)*. 2015;67(1):21-31.
- 560 47. Malfait F, Francomano C, Byers P, Belmont J, et al. (2017) The 2017 international
561 classification of the Ehlers-Danlos syndrome. *Am J Med Genet C Semin Med Genet*.
562 2017; 175(1):8-26.
- 563 48. Malfait, F., Hakim, A., Paepe, A. and Grahame, R. (2006) The genetic basis of the joint
564 hypermobility syndromes. *Rheumatology (Oxford)*. 45 (5), pp. 502-507.
- 565 49. McMaster W. Swimming injuries. *Sports Med*. 1996;22(5):332-336.
- 566 50. Mickelborough J, Van der Linden M, Richards J, Ennos A. Validity and reliability of a
567 kinematic protocol for determining foot contact events. *Gait Posture*. 2000;11:32-37.
- 568 51. Mundermann A, Dyrby C, Andriacchi T. Secondary gait changes in patients with
569 medial compartment knee osteoarthritis: increased load at the ankle, knee and hip
570 during walking. *Arthritis Rheum*. 2005;52(9):2835-2844.
- 571 52. O'Connell M, Burrows N, Van Vlijmen-Willems M, Clark S, Schalkwijk J. Tenascin-
572 X deficiency and Ehlers-Danlos syndrome: a case report and review of the literature.
573 *Br J Dermatol*.2010;16(6):1340-1345.
- 574 53. Orendurff M, Schoen J, Bernatz G, Segal A, Klute G. How humans walk: bout duration,
575 steps per bout, and rest duration. *J Rehabil Res Dev*. 2008;45(7):1077-1089.
- 576 54. Pallant, J. (2010). *SPSS survival manual*. 4th ed. London: McGraw.
- 577 55. Patla A. How is human gait controlled by vision. *Ecological Psychology*. 1998;10(3-
578 4):287-302.

- 579 56. Purser J, Golightly Y, Fenf Q, Helmick C, Renner J, Jordan J. Slower walking speed is
580 associated with incident knee osteoarthritis-related outcomes. *Arthritis Care Res*
581 (Hoboken). 2012;64(7):1028-1035.
- 582 57. Richards J. The measurement of human motion: a comparison of commercially
583 available systems. *Hum Mov Sci.* 1999;18:589-602.
- 584 58. Rigoldi C, Galli M, Cimolin V, Camerota F, Celletti C, Tenore N, Albertini G. Gait
585 strategy in patients with Ehlers-Danlos syndrome hypermobility type and Down
586 syndrome. *Res Dev Disabil.* 2012;33(5):1437-1442.
- 587 59. Ringsberg K, Cerdhem P, Johansson J, Obrant K. Is there a relationship between
588 balance, gait performance and muscular strength in 75-year-old women? *Age Aging.*
589 1999;28(3):289-293.
- 590 60. Riskowski J, Mikesky A, Bahamonde R, Alvey T, Burr D. Proprioception, gait
591 kinematics, and rates of loading during walking: are they related? *Journal of*
592 *Musculoskeletal and Neurological Interaction.* 2005;5(4):379-387.
- 593 61. Rombaut L, Malfait F, Cools, A, De Paepe A, Calders P. 2010. Musculoskeletal
594 complaints, physical activity and health-related quality of life among patients with the
595 Ehlers-Danlos syndrome hypermobility type. *Disabil Rehabil.* 2010;32(16):1339-1345.
- 596 62. Rombaut L, Malfait F, De Wandele I, Mahieu N, Thijs Y, Segers P, Paepe A, Claders
597 P. Muscle- tendon tissue properties in the hypermobility type Ehlers-Danlos
598 syndrome. *Arthritis Care Res (Hoboken).* 2012;64(5):766-772.
- 599 63. Rombaut L, Malfait F, De Wandele I, Thijs Y, Palmans T, De Paepe A, Calders P.
600 Balance, gait, falls, and fear of falling in women with the hypermobility type of Ehlers-
601 Danlos syndrome. *Arthritis Care Res (Hoboken).* 2011;63(10):1342-1439.
- 602 64. Rothman K. No adjustments are needed for multiple comparisons. *Epidemiology.*
603 1990;1(1):43-46.
- 604 65. Sahin, N, Baskent A, Ugurlu H, Berker E. Isokinetic evaluation of knee extensor/flexor
605 muscle strength in patients with hypermobility syndrome. *Rheumatology International.*
606 2008;28;643-648.
- 607 66. Samsa G, Edelman D, Rothman M, Willimans R, Lipscomb J, Matchar D. Determining
608 clinically important differences in health status measures. A general approach with
609 illustration to the health utilities index mark II. *Pharmacoeconomics.* 1999;15(2):141
610 – 155.
- 611 67. Scheper M, Engelbert R, Rameckers E, Verbunt J, Remvig L, Juul-Kristensen B.
612 Children with generalised joint hypermobility and musculoskeletal complaints: state of
613 the art diagnostics, clinical characteristics, and treatment. *Biomd Res Int.* 2013. doi:
614 10.1155/2013/121054.
- 615 68. Simic M, Hinman R, Wrigley T, Bennell K, Hunt M. Gait modification strategies for
616 altering knee joint load: A systematic review. *Arthritis Care Res (Hoboken).*
617 2011;63(3):405-426.
- 618 69. Simmonds J, Keer R. Hypermobility and the hypermobility syndrome. *Man Ther.*
619 2007;12:298-309.
- 620 70. Sinclair J, Taylor P, Greenhalgh A, Ddmundson C, Brooks D, Hobbs S. The test-retest
621 reliability of anatomical co-ordinate axes definition for the quantification of lower
622 extremity kinematics during running. *J Hum Kinet.* 2012;35:15-25.
- 623 71. Smith M. (2005) A review of the initial management of soft tissue sports injuries.
624 *Journal of Orthopaedic Nursing.* 2005;9:103-107.
- 625 72. Syx D, Symoens S, Steyaert W, De Paepe A, Coucke P, Malfait F. Ehlers-Danlos
626 syndrome, hypermobility type, is linked to chromosome 8p22-8p21.1 in an extended
627 Belgian family. *Dis Markers.* 2015. doi: 10.1155/2015/828970.

628 73. Tinkle B, Bird H, Grahame R, Lavallee M, Levy H. The lack of clinical distinction
629 between the hypermobility type of Ehlers-Danlos syndrome and the joint hypermobility
630 syndrome. *Am J Med Genet A*. 2009;149A:2368-2370.

631 74. Toker S, Soyucen E, Gulcan E, Kabay S, Ozbek O, Ozveren O, Aksakalli E, Cimbiz A.
632 Presentation of two cases with hypermobility syndrome and review of the literature.
633 *Eur J Phys Rehabil Med*. 2010;46(1):89-94.

634 75. Voermans N, Alfen N, Pillen S, Lammens M, Schalkwijk J, Zwarts M, Rooij I, Hamel
635 B, Engelen, B. Neuromuscular involvement in various types of Ehlers-Danlos
636 syndrome. *Annals of Neurology*. 2009;65(6):687-697.

637 76. Walker I. Statistics for psychology. Making sense of our world through analysis. 2007
638 [<http://staff.bath.ac.uk/pssiw/stats2/page2/page14/page14.html>].

639 77. Williamson, A. and Hoggart, B. (2005) Pain: a review of three commonly used pain
640 rating scales. *Journal of Clinical Nursing*. 14 (7), pp. 798-804.

641 78. Winter D. Human balance and posture control during standing and walking. *Gait*
642 *Posture*. 1995;3(4):193-214.

643 79. Yavuzer G, Oken O, Elhan A, Stam H. Repeatability of lower limb three-dimensional
644 kinematics in patients with stroke. *Gait Posture*. 2008;27(1):31-35.

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

8. TABLES

Table 1: The demographic characteristics of the JHS and the control group and pain intensity experienced during the last week at the lower limb joints.

Demographic characteristics	JHS group n = 29		Control group n = 30		p-value
	Mean	SD	Mean	SD	
Sex	27 women	2 men	28 women	2 men	0.94
Age (years)	37.57	13.77	39.27	12.59	0.62
BMI	27.27	6.12	25.45	3.08	0.15
Height (cm)	164.45	7.89	162.73	8.07	0.41
Weight (kg)	73.84	17.44	67.44	10.36	0.29
Beighton score	6.24	1.57	1.10	0.75	<0.001*
Hip pain during rest	3.54	2.85	0.06	0.32	0.001*
Hip pain during movement	3.97	2.97	0.05	0.20	0.001*
Knee pain during rest	2.62	2.51	0.09	0.38	0.001*
Knee pain during movement	3.27	2.73	0.05	0.22	0.001*
Ankle pain during rest	2.07	2.38	0.00	0.00	0.001*
Ankle pain during movement	2.89	2.61	0.00	0.00	0.001*

Key: BMI = body mass index; SD = standard deviation; * = statistically significant difference.

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

Table 2: The descriptive statistics and comparisons of gait spatiotemporal parameters of the JHS and the control group.

Spatiotemporal Parameters	JHS group n = 29	Control group n = 30	p-value	SMD (95% CI)
Speed (m/s)	1.14 (0.23)	1.33 (0.16)	0.001*	-0.96 (-1.49, -0.41)
Spatial parameters				
Stride length (m)	1.18 (0.25)	1.34 (0.12)	0.004*	-0.82 (-1.34, -0.28)
Step length (m)	0.61 (0.07)	0.67 (0.06)	0.004*	-0.92 (-1.45, -0.37)
Temporal parameters				
Stance duration %	60.30 (2.88)	58.71 (2.03)	0.018	0.64 (0.11, 1.15)
Double support duration %	20.49 (3.26)	18.09 (4.97)	0.034	0.57 (0.04, 1.08)
Initial double support duration %	10.44 (1.78)	8.57 (1.06)	0.001*	1.28 (0.71, 1.82)
Terminal double limb support duration %	10.26 (1.77)	8.75(1.26)	0.001*	0.99 (0.43, 1.51)

Key: Values are reported in mean (standard deviation). * Indicates statistically significant difference. SMD: standardised mean difference, CI: confidence interval. SMD of 0.5 and higher are highlighted in bold suggesting at least moderate differences [Cohen, 1988].

682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697

698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728

Table 3: Gait kinematics for the pelvis and hip joint during the stance, swing and initial contact (IC) phases for the JHS and control group.

Kinematic parameters (degrees)	JHS group n= 29	Control group n = 30	p-value	SMD (95% CI)
Maximum kinematics (Stance phase) (Degrees)				
Anterior pelvic tilt	8.46 (5.45)	6.97 (5.53)	0.30	0.27 (-0.24, 0.78)
Upward pelvic obliquity	2.92 (2.04)	3.52 (2.02)	0.26	-0.30 (-0.80, 0.22)
Internal pelvic rotation	6.46 (4.12)	7.25 (3.09)	0.40	-0.22 (-0.73, 0.30)
Hip flexion	26.41 (6.83)	28.46 (6.45)	0.24	-0.31 (-0.82, 0.21)
Hip adduction	9.81 (3.88)	10.15 (3.67)	0.73	-0.09 (-0.60, 0.42)
Hip internal rotation	6.19 (6.67)	6.74 (9.54)	0.80	-0.07 (-0.58, 0.44)
Maximum kinematics (Swing phase) (Degrees)				
Anterior pelvic tilt	8.14 (4.98)	6.97 (5.39)	0.39	0.23 (-0.29, 0.73)
Upward pelvic obliquity	3.62 (2.28)	4.88 (2.13)	0.03	-0.57 (-1.08, -0.04)
Internal pelvic rotation	6.25 (4.21)	7.03 (2.65)	0.39	-0.22 (-0.73, 0.29)
Hip flexion	27.42 (6.59)	28.77 (6.58)	0.43	-0.21 (-0.71, 0.31)
Hip adduction	5.51 (3.27)	4.77 (2.93)	0.36	0.24 (-0.28, 0.75)
Hip internal rotation	1.20 (6.81)	2.78 (5.25)	0.32	-0.26 (-0.77, 0.26)
Minimum Kinematics (Stance phase) (Degrees)				
Posterior pelvic tilt	4.88 (5.16)	4.15 (5.12)	0.59	0.14 (-0.37, 0.65)
Downward pelvic obliquity	-3.96 (2.27)	-4.99 (2.01)	0.07	0.48 (-0.04, 0.99)
External pelvic rotation	-6.48 (2.68)	-6.78 (3.23)	0.70	0.10 (-0.41, 0.61)
Hip extension	-8.54 (7.91)	-11.89 (7.81)	0.10	0.43 (-0.10, 0.94)
Hip abduction	-0.58 (3.81)	-2.09 (3.42)	0.11	0.42 (-0.10, 0.93)
Hip external rotation	-7.04 (7.34)	-7.89 (8.00)	0.67	0.11 (-0.40, 0.62)
Minimum kinematics (swing phase) (Degrees)				
Posterior pelvic tilt	5.20 (4.93)	4.26 (5.10)	0.47	0.19 (-0.33, 0.70)
Downward pelvic obliquity	-1.98 (1.60)	-1.77 (1.95)	0.65	-0.12 (-0.63, 0.39)
External pelvic rotation	-4.59 (2.79)	-4.61 (3.02)	0.98	0.01 (-0.50, 0.52)
Hip extension	-1.71 (8.12)	-4.61 (7.03)	0.14	0.38 (-0.14, 0.89)
Hip abduction	-2.91 (3.49)	-4.73 (2.71)	0.02	0.58 (0.06, 1.10)
Hip external rotation	-8.38 (7.09)	-8.25 (5.66)	0.93	-0.02 (-0.53, 0.49)

Kinematics (initial contact) (Degrees)				
Pelvic tilt	6.72 (5.21)	5.86 (5.44)	0.53	0.16 (-0.35, 0.67)
Pelvic obliquity	-0.69 (1.71)	-0.04 (1.85)	0.17	-0.36 (-0.87, 0.15)
Pelvic rotation	5.76 (4.51)	6.79 (3.42)	0.32	-0.26 (-0.77, 0.26)
Hip flexion/extension	25.64 (6.84)	27.03 (7.12)	0.44	-0.20 (-0.71, 0.32)
Hip abduction/adduction	2.81 (4.08)	1.45 (3.70)	0.18	0.35 (-0.17, 0.86)
Hip internal/external rotation	-4.60 (8.47)	-5.53 (7.92)	0.66	0.11 (-0.40, 0.62)

Key: Values are reported in mean (standard deviation). SMD: standardised mean difference, CI: confidence interval. SMD of 0.5 and higher are highlighted in bold suggesting at least differences [Cohen, 1988]. When values are positive, the knee is in flexion/valgus position.

729
730
731
732
733
734
735
736
737

Table 4: Gait kinematics for the knee and ankle joints during the stance, swing and initial contact phases for the JHS and control group.

Knee kinematic parameters (degrees)	JHS group n = 29	Control group n = 30	p-value	SMD (95% CI)
Maximum kinematics (stance phase) (Degrees)				
Knee flexion	34.27 (7.76)	34.73 (7.04)	0.81	-0.06 (-0.57, 0.45)
Knee valgus	6.77 (3.73)	5.59 (3.17)	0.19	0.34 (-0.18, 0.85)
Ankle dorsiflexion	8.24 (4.49)	8.26 (2.73)	0.98	-0.01 (-0.52, 0.51)
Foot internal progression	8.23 (6.34)	7.58 (5.02)	0.66	0.11 (-0.40, 0.62)
Ankle internal rotation	9.00 (6.45)	9.52 (4.63)	0.72	-0.09 (-0.60, 0.42)
Maximum kinematics (swing phase) (Degrees)				
Knee flexion	55.04 (7.68)	59.19 (5.15)	0.01*	-0.64 (-1.15, -0.11)
Knee valgus	8.51 (3.23)	8.08 (3.30)	0.62	0.13 (-0.38, 0.64)
Ankle dorsiflexion	2.14 (4.71)	0.83 (4.60)	0.28	0.28 (-0.42, 0.79)
Foot internal progression	0.77 (6.68)	0.27 (5.38)	0.51	0.08 (-0.43, 0.59)
Ankle internal rotation	3.21 (5.23)	3.31 (4.69)	0.94	-0.02 (-0.53, 0.49)
Minimum kinematics (stance phase) (Degrees)				

Knee extension	1.32 (4.34)	0.49 (3.62)	0.42	0.21 (-0.31, 0.72)
Knee varus	0.71 (3.70)	0.25 (3.05)	0.60	0.14 (-0.38, 0.65)
Ankle plantar flexion	-17.09 (8.40)	-16.98 (4.92)	0.61	-0.02 (-0.53, 0.49)
Foot external progression	-6.77 (5.54)	-5.90 (3.24)	0.46	-0.19 (-0.70, 0.32)
Ankle external rotation	-6.56 (6.27)	-5.92 (3.68)	0.63	-0.13 (-0.63, 0.39)
Minimum kinematics (swing phase) (Degrees)				
Knee extension	-1.94 (5.10)	-2.62 (5.04)	0.60	0.13 (-0.38, 0.64)
Knee varus	-0.36 (3.71)	-0.52 (2.77)	0.85	0.05 (-0.46, 0.56)
Ankle plantar flexion	-21.66 (8.20)	-21.44 (6.26)	0.90	-0.03 (-0.54, 0.48)
Foot external progression	-8.25 (5.95)	-8.66 (5.24)	0.78	0.07 (-0.44, 0.58)
Ankle external rotation	-9.02 (5.63)	-10.51 (6.28)	0.34	0.25 (-0.27, 0.76)
Kinematics (initial contact) (Degrees)				
Knee flexion/extension	2.73 (4.02)	3.25 (3.39)	0.59	-0.14 (-0.65, 0.37)
Knee valgus/varus	5.16 (4.17)	3.96 (3.21)	0.22	0.32 (-0.19, 0.83)
Ankle dorsi/plantar flexion	-5.03 (8.07)	-3.31 (2.75)	0.27	-0.29 (-0.80, 0.23)
Foot progression	-4.31 (5.46)	-4.28 (5.21)	0.98	-0.01 (-0.52, 0.50)
Ankle internal/external rotation	-0.12 (4.68)	0.25 (3.58)	0.72	-0.09 (-0.60, 0.42)
<i>Key: Values are reported in mean (standard deviation). * Indicates statistically significant difference. SMD: standardised mean difference, CI: confidence interval. SMD of 0.5 and higher are highlighted in bold suggesting at least moderate differences [Cohen, 1988].</i>				

738

739

740

741

742

743

744

745

746

747

748
749
750
751
752
753
754
755
756
757
758
759

Table 5: Gait moment and power generated and absorbed at the hip, knee and ankle joints in the sagittal, frontal and transverse planes for the JHS and control group.

Moment (Nm/kg) and power (Watts/kg) parameters	JHS group n = 29	Control group n = 30	p- value	SMD (95% CI)
Maximum moment (Nm/kg)				
Hip flexion/extension	0.50 (0.20)	0.65 (0.22)	0.01*	-0.71 (-1.23, -0.18)
Hip abduction/adduction	0.92 (0.25)	0.95 (0.14)	0.42	-0.15 (-0.66, 0.36)
Hip internal/external rotation	0.07 (0.03)	0.09 (0.04)	0.07	-0.56 (-1.08, -0.04)
Maximum power generation (Watts/kg)				
Hip flexion/extension	0.70 (0.30)	0.84 (0.28)	0.08	-0.48 (-0.99, 0.04)
Hip abduction/adduction	0.59 (0.24)	0.65 (0.17)	0.06	-0.29 (-0.80, -0.23)
Hip internal/external rotation	0.14 (0.14)	0.12 (0.16)	0.66	0.13 (-0.38, 0.64)
Minimum moment (Nm/kg)				
Hip flexion/extension	-0.57 (0.23)	-0.66 (0.16)	0.09	0.46 (-0.07, 0.97)
Hip abduction/adduction	-0.13 (0.08)	-0.13 (0.06)	0.66	0.00 (-0.51, 0.51)
Hip internal to external rotation	-0.19 (0.08)	-0.20 (0.09)	0.80	0.12 (-0.40, 0.63)
Minimum power absorption (Watts/kg)				
Hip flexion/extension	-0.61 (0.69)	-0.56 (0.26)	0.23	-0.10 (-0.61, 0.42)
Hip abduction/adduction	-0.53 (0.30)	-0.54 (0.29)	0.66	0.03 (-0.48, 0.54)
Hip internal/external rotation	-0.26 (0.17)	-0.33 (0.18)	0.12	0.40 (-0.12, 0.91)
Maximum moment (Nm/kg)				
Knee flexion/extension	0.41 (0.15)	0.51 (0.22)	0.04	-0.53 (-1.04, 0.00)
Knee valgus/varus	0.12 (0.05)	0.11 (0.06)	0.07	0.18 (-0.33, 0.69)
Knee internal/external rotation	0.09 (0.05)	0.12 (0.04)	0.02	-0.66 (-1.18, -0.13)
Maximum power generation (Watts/kg)				

Knee flexion/extension	0.54 (0.29)	0.71 (0.31)	0.01*	-0.57 (-1.08, 0.04)
Knee valgus/varus	0.08 (0.04)	0.10 (0.06)	0.32	-0.39 (-0.90, 0.13)
Knee internal/external rotation	0.11 (0.12)	0.27 (0.89)	0.45	-0.25 (-0.76, 0.27)
Minimum moment (Nm/kg)				
Knee flexion/extension	-0.32 (0.15)	-0.38 (0.13)	0.06	0.43 (-0.09, 0.94)
Knee valgus/varus	-0.27 (0.14)	-0.31 (0.11)	0.56	0.32 (-0.20, 0.83)
Knee internal/external rotation	-0.10 (0.04)	-0.12 (0.04)	0.04	0.50 (-0.02, 1.01)
Minimum power absorption (Watts/kg)				
Knee flexion/extension	-0.77 (0.39)	-0.95 (0.48)	0.11	0.41 (-0.11, 0.92)
Knee valgus/varus	-0.14 (0.09)	-0.15 (0.10)	0.62	0.11 (-0.41, 0.61)
Knee internal/external rotation	-0.10 (0.04)	-0.14 (0.05)	0.001*	0.88 (0.34, 1.40)
Maximum moment (Nm/kg)				
Ankle dorsi/plantar flexion	1.24 (0.18)	1.33 (0.12)	0.05	-0.59 (-1.10, -0.06)
Foot progression	0.28 (0.11)	0.26 (0.10)	0.36	0.19 (-0.32, 0.70)
Ankle internal/external rotation	0.02 (0.01)	0.02 (0.03)	0.51	0.00 (-0.51, 0.51)
Maximum power generation (Watts/kg)				
Ankle dorsi/plantar flexion	2.68 (0.86)	3.08 (0.82)	0.08	-0.48 (-0.99, 0.05)
Foot progression	0.38 (0.29)	0.28 (0.23)	0.13	0.38 (-0.14, 0.89)
Ankle internal/external rotation	0.09 (0.21)	0.02 (0.02)	0.27	0.47 (-0.05, 0.98)
Minimum moment (Nm/kg)				
Ankle dorsi/plantar flexion	-0.11 (0.05)	-0.13 (0.03)	0.17	0.49 (-0.04, 1.00)
Foot progression	-0.05 (0.06)	-0.05 (0.03)	0.39	0.00 (-0.51, 0.51)
Ankle internal/external rotation	-0.10 (0.04)	-0.13 (0.05)	0.10	0.66 (0.13, 1.18)
Minimum power absorption (Watts/kg)				
Ankle dorsi/plantar flexion	-0.81 (0.67)	-0.67 (0.25)	0.64	-0.28 (-0.79, 0.24)
Foot progression	-0.17 (0.10)	-0.15 (0.08)	0.58	-0.22 (-0.73, 0.29)
Ankle internal/external rotation	-0.36 (1.01)	-0.12 (0.06)	0.06	-0.34 (-0.85, 0.18)
<i>Keys: Values are reported in mean (standard deviation). * Indicates statistically significant difference. SMD: standardised mean difference, CI: confidence interval. SMD of 0.5 and higher are highlighted in bold suggesting at least moderate differences [Cohen, 1988].</i>				

760

761

762

763

764

765

766

767

768

769

Table 6: Multiple regression between gait parameters found to be significantly reduced in the JHS group with age, body weight, back pain, hip pain, knee pain and ankle pain.

	R Square	Percentage	ANOVA P value	Beta standardized coefficient	Coefficient P value
Speed	0.162	16.2%	0.155	Knee pain = -0.241	0.230
Maximum knee flexion during the swing phase	0.136	13.6%	0.245	Ankle pain = -0.326	0.187
Hip maximum moment in the sagittal plane	0.123	12.3%	0.315	Back pain = -0.236	0.110
Knee maximum power generation in the sagittal plane	0.168	16.8%	0.127	Knee pain = -0.397	0.047
Knee minimum power absorption in the transverse plane	0.304	30.4%	0.003*	Knee pain = 0.661	0.007*

Keys: *Indicates statistically significant difference at $p < 0.01$.

770

771

772

773


9. FIGURES LEGENDS

774 **Figure 1:** Curve graphs showing the kinematics of the lower limb joints during the gait cycle at sagittal, frontal,
 775 and transverse planes for the JHS group; n = 29, the control group; n = 30. The solid line displays the mean and
 776 the semi-transparent line displays the standard deviation. The vertical line separate between the stance and swing
 777 phase in gait graphs. JHS group graphs were compared against the control group graph. ↓ indicates statistically
 778 significant reduction in kinetics in the JHS group when compared to the control group.

779 **Figure 2:** Curve graphs showing the kinetics acting at the lower limb joints during the gait cycle for the JHS; n
 780 = 29, and control group; n = 30. The solid line illustrates the mean and the semi-transparent line illustrates the
 781 standard deviation. The vertical line separate between the stance and swing phase in gait graphs. JHS group
 782 graphs were compared against the control group graph. ↓ indicates statistically significant reduction in
 783 kinetics in the JHS group when compared to the control group.

784

FIGURES




	Control Group			
Hip	JHS group			
	Control group			
Knee	JHS group			N/A
	Control group			N/A
Ankle	JHS group		N/A	
	Control group		N/A	

785

786

Gait kinetics

Figure 2: Curve graphs showing the kinetics acting at the lower limb joints during the gait cycle for the JHS; $n = 29$, and control group; $n = 30$. The solid line illustrates the mean and the semi-transparent line illustrates the standard deviation. The vertical line separate between the stance and swing phase in gait graphs. JHS group graphs were compared against the control group graph. ↓ indicates statistically significant reduction in kinetics in the JHS group when compared to the control group.



787

788

789